Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701
- Conditions
- Infection, Human Immunodeficiency Virus
- Registration Number
- NCT00453440
- Lead Sponsor
- ViiV Healthcare
- Brief Summary
This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.
The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin.
They will be asked to give two samples to test for the presence of the genetic marker HLA-B\*5701. The two samples are:
* A cheek swab
* A blood sample
In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B\*5701 testing.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1502
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of HLA-B*5701 in the UK population via central labs 2 Hours The widespread of HLA-B\*5701 applied in the selected area in each participant of the UK population was tested via central labs. The result is summarized here.
- Secondary Outcome Measures
Name Time Method Prevalence of HLA-B*5701 in major UK ethnotypes in the study population. 2 Hours Description of HLA-B*5701 in the UK population via local labs. 2 Hours
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧London, United Kingdom